Patents by Inventor Marietta TURECEK

Marietta TURECEK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF ADAMTS13 FOR TREATING, AMELIORATING AND/OR PREVENTING VASO-OCCLUSIVE CRISIS IN SICKLE CELL DISEASE, ACUTE LUNG INJURY AND/OR ACUTE RESPIRATORY DISTRESS SYNDROME
    Publication number: 20220047688
    Abstract: The disclosure provides compositions and methods for treating, ameliorating, and/or preventing a vaso-occlusive crisis (VOC) in a subject suffering from sickle cell disease (SCD). The disclosure also provides compositions and methods for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS). The disclosure provides A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMTS13) or a composition comprising ADAMTS13 for treating, ameliorating, and/or preventing the VOC, or for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from ALI and/or ARDS.
    Type: Application
    Filed: November 1, 2021
    Publication date: February 17, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Bruce EWENSTEIN, Brahm GOLDSTEIN, Bernhard MAJER, Paolo ROSSATO, Friedrich SCHEIFLINGER, Marietta TURECEK
  • Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
    Patent number: 11191818
    Abstract: The disclosure provides compositions and methods for treating, ameliorating, and/or preventing a vaso-occlusive crisis (VOC) in a subject suffering from sickle cell disease (SCD). The disclosure also provides compositions and methods for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS). The disclosure provides A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMTS13) or a composition comprising ADAMTS13 for treating, ameliorating, and/or preventing the VOC, or for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from ALI and/or ARDS.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: December 7, 2021
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Bruce Ewenstein, Brahm Goldstein, Bernhard Majer, Paolo Rossato, Friedrich Scheiflinger, Marietta Turecek
  • USE OF ADAMTS13 FOR TREATING, AMELIORATING AND/OR PREVENTING VASO-OCCLUSIVE CRISIS IN SICKLE CELL DISEASE, ACUTE LUNG INJURY AND/OR ACUTE RESPIRATORY DISTRESS SYNDROME
    Publication number: 20190336588
    Abstract: The disclosure provides compositions and methods for treating, ameliorating, and/or preventing a vaso-occlusive crisis (VOC) in a subject suffering from sickle cell disease (SCD). The disclosure also provides compositions and methods for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS). The disclosure provides A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMTS13) or a composition comprising ADAMTS13 for treating, ameliorating, and/or preventing the VOC, or for treating, ameliorating, and/or preventing lung injury in a subject suffering from or at risk of suffering from ALI and/or ARDS.
    Type: Application
    Filed: August 4, 2017
    Publication date: November 7, 2019
    Applicants: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Bruce EWENSTEIN, Brahm GOLDSTEIN, Bernhard MAJER, Paolo ROSSATO, Friedrich SCHEIFLINGER, Marietta TURECEK